CADL — Stock Film
STOCK FILMSCENE 1/11CADL · $13.13
Stock Expert AI presents
CADL
Candel Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Candel Therapeutics, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 55 employees. Now — the numbers.

on the stock market since 2021
55 employees
$558.9M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $1.9M
At this pace, that money lasts about 3.1 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

Every quarter, analysts set a profit bar.
How many of the last 7 did the company clear?
3 / 7
EXPECTATIONS MET OR BEATEN
3
Mar 2025
May 2025
Aug 2025
Nov 2025
Mar 2026
May 2026
Aug 2026
3 TIMES IN THE LAST 7 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
40
weak

Clearly below the class average.

FINANCIAL STRENGTH
49
weak

Clearly below the class average.

VALUATION
44
weak

Clearly below the class average.

GROWTH
13
very weak

Clearly below the class average.

PRICE MOMENTUM
94
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
A strong cash pile8/10
Few are betting against it10/10
WEAK SPOTS
Thin profit on each sale3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/3
Strong cash, light debt

There is $119.7M in the vault; even if every debt were paid off, $117.8M would remain.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 23 buys and 5 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $22.5071% above today’s price.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $38.2M against $0 in annual sales.

2
THE RISKS · 2/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 13/100.

3
THE RISKS · 3/3
The business trails its class

Measured against its sector, the quality of the business sits below the class average. Report-card grade: 40/100.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, CADL sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: CADL is a high-risk stock — not yet profitable, and its future rides on its product catching on.

Analysts’ average target sits above today’s price, yet the valuation grade (44/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film